Ask AI
Advances from EHA and ICML 2025

CME

Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: March 24, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following accurately describes the mechanism of action of the investigational agent surovatamig?

2.

A 75-year-old man (Eastern Cooperative Oncology Group performance status 1) presents with newly diagnosed mantle cell lymphoma (MCL) with high-risk biology (Ki-67 40%, TP53 mutation). Which of the following treatments would you recommend for this patient if their goal was to optimize their outcomes?

3.

Did the POLARGO trial of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) compared with R-GemOx in transplant-ineligible patients with R/R DLBCL show significant improvement in response, PFS, or OS, or were the results similar between treatment arms?